Alpha Tau Medical Ltd. (DRTS) Fair Value 2026

DRTS · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (40/100)

Quick Summary — As of 2026-08-27, Alpha Tau Medical Ltd. (DRTS) trades at $14.81. QOC: 2.6/10. Value Trap Risk: 40/100 (WARN). 0/13 models active.

Key Facts

Ticker
DRTS
Price
$14.81
Quality Score
2.6/10
Value Trap Risk
40/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 40 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give DRTS?

0 Intrinsic Value Models vs. Current Price ($14.81)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Alpha Tau Medical Ltd. (DRTS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Alpha Tau Medical Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About DRTS?

0 of 13 models are currently active for DRTS. See which stocks rank higher →

How Does DRTS Rank in Biotechnology?

Among 620 Biotechnology stocks, DRTS ranks #597 by Quality of Company score. CirclFi's QOC score of 2.6/10 evaluates 32 fundamental signals. A score of 2.6 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Alpha Tau Medical Ltd. competes in an environment where pipeline depth and stage distribution often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is DRTS a Value Trap?

CirclFi's Value Trap algorithm assigns DRTS a score of 40/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Alpha Tau Medical Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Alpha Tau Medical Ltd. is rated at 2.6/10. This weak-tier score exhibits fundamental weaknesses that warrant careful scrutiny.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every DRTS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Alpha Tau Medical Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

YDESYD Bio LtdQOC 2.8PHARPharming Group N.V.QOC 2.6MAJINextel Medical Corp.QOC 2.9SLGLSol-Gel Technologies Ltd.QOC 2.6ARGXargenx SEQOC 2.9OKYOOKYO Pharma LimitedQOC 2.5IOVAIovance Biotherapeutics, Inc.QOC 6.1KAPAKairos Pharma, Ltd.QOC 5.1UNCYUnicycive Therapeutics, Inc.QOC 4.5EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: YDES · PHAR · MAJI · SLGL · ARGX · OKYO · IOVA · KAPA · UNCY · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to DRTS?

7 companies across all industries closest to DRTS’s Quality of Company score of 2.6/10.

ZKINZK International Group Co., Ltd.QOC 2.6SNTGSentage Holdings Inc.QOC 2.6APWCAsia Pacific Wire & Cable Corporation LimitedQOC 2.6CMCLCaledonia Mining Corporation PlcQOC 2.6KMDAKamada Ltd.QOC 2.6HUDIHuadi International Group Co., Ltd.QOC 2.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ZKIN · SNTG · APWC · CMCL · KMDA · HUDI · NVDA

Where Does DRTS Sit in CirclFi's Biotechnology Rankings?

DRTS is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Alpha Tau Medical Ltd.’s Valuation?

What is Alpha Tau Medical Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Alpha Tau Medical Ltd. (DRTS). The Quality of Company score is 2.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is DRTS overvalued or undervalued right now?

At $14.81, 0 of 0 active models suggest DRTS may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Alpha Tau Medical Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 2.6 mean for DRTS?

Alpha Tau Medical Ltd.'s QOC of 2.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on DRTS?

CirclFi analyzes DRTS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is DRTS a value trap in 2026?

Alpha Tau Medical Ltd.'s Value Trap score is 40/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Alpha Tau Medical Ltd. (DRTS) a Quality of Company score of 2.6/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/DRTS/ · Methodology
Primary sources for this DRTS valuation
  • Financial statements: Alpha Tau Medical Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001871321) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for DRTS as of ; valuations recomputed .